These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26139339)

  • 21. Dalfampridine effects on cognition, fatigue, and dexterity.
    Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
    Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
    Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J; Blight AR; Goodman A; Lynn F; Putzki N
    Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing dalfampridine efficacy in the physician's office.
    Raffel JB; Malik O; Nicholas RS
    Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI; Sobieraj DM; Marinucci LN
    Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
    Valet M; El Sankari S; Van Pesch V; Detrembleur C; Lejeune T; Stoquart G
    Clin Biomech (Bristol); 2021 Jun; 86():105382. PubMed ID: 34000628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O; Berger T; Hartung HP; Putzki N
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical response and tolerability of fampridine in clinical practice.
    Costa-Arpín E; Pato A; Rodríguez-Regal A; Midaglia L; Yáñez R; Muñoz D; Lorenzo JR; Amigo C; Prieto JM
    Neurodegener Dis Manag; 2016 Apr; 6(2):99-105. PubMed ID: 27032814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
    Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial.
    Luca CC; Nadayil G; Dong C; Nahab FB; Field-Fote E; Singer C
    J Neurol Sci; 2017 Aug; 379():7-11. PubMed ID: 28716283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
    NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
    J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
    J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gait disorders in multiple sclerosis.
    Bethoux F
    Continuum (Minneap Minn); 2013 Aug; 19(4 Multiple Sclerosis):1007-22. PubMed ID: 23917098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalfampridine in multiple sclerosis.
    Goodman AD; Hyland M
    Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of the dynamic gait index in people with multiple sclerosis.
    Forsberg A; Andreasson M; Nilsagård YE
    Phys Ther; 2013 Oct; 93(10):1369-76. PubMed ID: 23641026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.
    Grobelny A; Behrens JR; Mertens S; Otte K; Mansow-Model S; Krüger T; Gusho E; Bellmann-Strobl J; Paul F; Brandt AU; Schmitz-Hübsch T
    PLoS One; 2017; 12(12):e0189281. PubMed ID: 29244874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.